Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | MMP2 | P08253 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1465587 | 0.92 | TDP1 (0.46) | ALDH1A1TDP1PKMLMNAHTT | |
| SCHEMBL1074499 | 0.84 | ALDH1A1 (0.52) | ALDH1A1PKMLMNAHTTMAPK1 | |
| SCHEMBL1656632 | 0.82 | TDP1 (0.57) | ALDH1A1TDP1LMNAHTTMEN1 | |
| SCHEMBL10787975 | 0.80 | TDP1 (0.59) | ALDH1A1TDP1PKMLMNA | |
| SCHEMBL10784720 | 0.80 | TDP1 (0.70) | ALDH1A1TDP1HTTMAPK1MEN1 | |
| SCHEMBL1081632 | 0.79 | HCAR3 (0.49) | ALDH1A1TDP1PKMLMNAMAPK1 | |
| SCHEMBL4255397 | 0.78 | TDP1 (0.55) | ALDH1A1TDP1LMNAMAPK1KMT2A | |
| SCHEMBL1083207 | 0.77 | MAPT (0.60) | ALDH1A1TDP1LMNAMAPK1MEN1 | |
| SCHEMBL1465465 | 0.77 | ALDH1A1 (0.50) | ALDH1A1PKMLMNAHTTMAPK1 | |
| SCHEMBL3512673 | 0.76 | TDP1 (0.62) | ALDH1A1TDP1LMNAHTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071197-A1 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | BIOLIPOX AB (LV) | 2011-03-24 | — | — | US | disclosed |
| EP-2274280-A2 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | Biolipox AB (SE) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009127822-A2 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | BIOLIPOX AB (SE) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071197-A1 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | LTC4S, LTB4R2, LTB4R | ALDH1A1 474/4885TDP1 4176/4885PKM 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.